[{"orgOrder":0,"company":"Unnatural Products","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Macrocyclic Peptide","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Unnatural Products","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Unnatural Products \/ BridgeBio Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Unnatural Products \/ BridgeBio Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Unnatural Products

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof
                          Not Confirmed
                          Cosmoprof
                          Not Confirmed

                          Details : Under the terms of the agreement, UNP assumed responsibility for R&D, and BridgeBio will assume the further development of the macrocyclic peptide candidates for rare diseases and oncology.

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : Macrocyclic Peptide

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : BridgeBio Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank